Clinical trials: Leukemia, Myeloid
Acute Myeloid Leukemia, B-cell Non-Hodgkin Lymphoma
PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies
This is a Phase 1 dose-escalation study of PRT1419, a myeloid cell leukemia-1 (MCL-1) inhibitor, in participants with selected relapsed/refractory myeloid or B-cell malignancies.
- Conditions
- Acute Myeloid Leukemia, B-cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelomonocytic Leukemia
- Trial name
- NCT05107856
- Testing
- PRT1419, Azacitidine, Venetoclax
- Where
- 9 sites in United States
- Volunteers
- 21 people
- Sponsor
- Prelude Therapeutics Incorporated
Leukemia, Myeloid, Acute
Volasertib + Decitabine in Patients With Acute Myeloid Leukemia (AML)
Dose Escalation (MTD Finding) Phase: To investigate the maximum tolerated dose (MTD), safety and pharmacokinetics of different volasertib administration schedules in combination with decitabine in previously untreated AML…
- Trial name
- NCT02003573
- Testing
- decitabine iv, volasertib iv infusion
- Where
- 3 sites in United States
- Volunteers
- 13 people
- Sponsor
- Boehringer Ingelheim
Myelodysplastic Syndromes, Higher Risk Myelodysplastic Syndromes
Study of REM-422 in Patients With AML or Higher Risk MDS
The goal of this study is to determine the safety and antitumor effects of REM-422, a MYB mRNA degrader, in people with Higher Risk MDS and relapsed/refractory AML
- Conditions
- Myelodysplastic Syndromes, Higher Risk Myelodysplastic Syndromes, Acute Myeloid Leukemia, Acute Myeloid Leukemia Refractory
- Trial name
- NCT06297941
- Testing
- REM-422
- Where
- 9 sites in United States, France
- Volunteers
- 100 people
- Sponsor
- Remix Therapeutics
Leukemia, Myeloid, Acute
A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies
The purpose of this study is to determine the recommended Phase 2 dose (RP2D) candidate(s) of bleximenib in combination with AML directed therapies (dose selection) and further to evaluate safety and tolerability of bleximenib in…
- Trial name
- NCT05453903
- Testing
- Bleximenib, Venetoclax (VEN), Azacitidine (AZA)
- Where
- 32 sites in United States, Australia and 6 more
- Volunteers
- 196 people
- Sponsor
- Janssen Research & Development, LLC
Chronic Myeloid Leukemia
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
The purpose of this study is to compare the efficacy of ponatinib and imatinib in patients with newly diagnosed chronic myeloid leukemia (CML) in the chronic phase.
- Trial name
- NCT01650805
- Testing
- ponatinib, imatinib (Gleevec/ Glivec)
- Where
- 170 sites in United States, Australia and 22 more
- Volunteers
- 307 people
- Sponsor
- Ariad Pharmaceuticals
Acute Myeloid Leukemia, Myelodysplastic Syndromes
ACHIEVE2 - Safety and Preliminary Efficacy of Intravenous TCB008 in Patients With Relapse or Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)/AML
TCB008-003 (ACHIEVE2) is an open-label, multi-center study conducted in 2 parts (dose escalation followed by dose expansion) to evaluate safety, persistence/expansion, and preliminary efficacy of single and multiple intravenous…
- Trial name
- ACHIEVE2 (NCT06463327)
- Testing
- TCB008
- Volunteers
- 69 people
- Sponsor
- TC Biopharm
Acute Myeloid Leukemia
Single Dose Study With 4SC-203 in Healthy Volunteers
The purpose of the study is to evaluate safety and tolerability of 4SC-203 after a single dose administration in healthy volunteers.
- Trial name
- NCT01054937
- Testing
- 4SC-203
- Where
- Germany
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- 4SC AG
Acute Myeloid Leukemia (AML)
Treatment Patterns and Key Healthcare Resource Use in Acute Myeloid Leukemia (AML) With or Without FMS-like Tyrosine Kinase-3 (FLT3) Mutation Study Based on Retrospective Chart Review
The purpose of this study is to retrospectively evaluate the treatment patterns and AML-related key healthcare resource use among AML patients, stratified by FLT3 mutation status, intensive chemotherapy (IC) eligibility, and…
- Trial name
- NCT03047083
- Testing
- Treatment patterns among AML patients, AML-related healthcare resources
- Where
- United States
- Volunteers
- 1,027 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Chronic Myeloid Leukemia (CML)
Metabolic Outcomes in Patients Receiving Tyrosine Kinase Inhibitor (TKI) Therapy With Dasatinib or Nilotinib
The purpose of this study was to determine how often and how likely patients are to develop Type 2 Diabetes or high cholesterol/lipids when receiving dasatinib or nilotinib as therapy for Chronic Myelogenous Leukemia (CML).
- Trial name
- NCT02733445
- Testing
- dasatinib, nilotinib
- Volunteers
- 2,650 people
- Sponsor
- Bristol-Myers Squibb
Refractory Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia
Study of Fosciclopirox in Patients With Relapsed/Refractory Acute Myeloid Leukemia
This will be an open-label, Phase 1B/2A, study to characterize the efficacy, safety, pharmacokinetics, and pharmacodynamics of fosciclopirox administered alone and in combination with cytarabine in patients with R/R AML with up…
- Trial name
- NCT04956042
- Testing
- Fosciclopirox, Fosciclopirox + Cytarabine
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- CicloMed LLC
Acute Myeloid Leukemia (AML)
A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Participants With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy
Acute Myeloid Leukaemia (AML) is an aggressive and rare cancer of myeloid cells (a white blood cell responsible for fighting infections).
- Trial name
- Viale-a (NCT02993523)
- Testing
- Azacitidine, Venetoclax
- Where
- 172 sites in United States, Australia and 27 more
- Volunteers
- 443 people
- Sponsor
- AbbVie
Leukemia, Myelodysplastic Syndromes
VNP40101M in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndrome
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of VNP40101M in treating patients who have relapsed or…
- Conditions
- Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
- Trial name
- NCT00049686
- Testing
- laromustine
- Where
- United States
- Sponsor
- Vion Pharmaceuticals
Invasive Aspergillosis, Invasive Pulmonary Aspergillosis
VL-2397 Compared to Standard First-Line Treatment for Invasive Aspergillosis (IA) in Adults
The purpose of the trial is to evaluate the safety and efficacy of a new antifungal with a novel mechanism of action in immunocompromised adults with invasive aspergillosis.
- Trial name
- NCT03327727
- Testing
- Investigational Agent: VL-2397, Standard treatment: Voriconazole, Isavuconazole, or Liposomal amphotericin B
- Where
- 28 sites in United States, Belgium and 4 more
- Volunteers
- 4 people
- Sponsor
- Vical
Chronic Myeloid Leukemia
Compare Bosutinib To Imatinib In Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive CML
Two-arm, randomized, open-label trial designed to evaluate the efficacy and safety of bosutinib alone compared to imatinib alone in subjects newly diagnosed with chronic phase Chronic Myelogenous Leukemia (CML).
- Trial name
- NCT00574873
- Testing
- Bosutinib, imatinib
- Where
- 165 sites in United States, Argentina and 27 more
- Volunteers
- 502 people
- Sponsor
- Pfizer
Acute Myelogenous Leukemia (AML), Acute Lymphoblastic Leukemia (ALL)
Non-interventional, Long-term Follow-up of Subjects Who Completed ApoGraft-01 Study
This is a non-interventional, long-term follow-up study in subjects who received ApoGraft in study ApoGraft-01. Up to 12 subjects who completed ApoGraft-01 study will be offered to participate in this follow-up study.
- Conditions
- Acute Myelogenous Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Non Hodgkin Lymphoma (NHL), Hodgkin Lymphoma, Adult
- Trial name
- NCT03260101
- Testing
- non intervational
- Where
- Israel
- Volunteers
- 12 people
- Sponsor
- Cellect Biotechnology
Leukemia, Leukemia, Myeloid
Philadelphia Chromosome Positive CML Patients Without Optimal Response or Tolerance to Bcr-Abl TKI
A Phase I/II multicenter study of IY5511HCl in Philadelphia chromosome positive chronic myeloid leukemia patients without optimal response or tolerance to Bcr-Abl tyrosine kinase inhibitors (Imatinib and/ or Dasatinib, Nilotinib)…
- Conditions
- Leukemia, Leukemia, Myeloid, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Philadelphia Chromosome
- Trial name
- NCT01602952
- Testing
- Radotinib
- Where
- 12 sites in India, South Korea and 1 more
- Volunteers
- 85 people
- Sponsor
- Il-Yang Pharm. Co., Ltd.
Leukemia, Myeloid, Acute
A Study of Cusatuzumab Plus Azacitidine in Japanese Participants With Newly Diagnosed Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome Who Are Not Candidates for Intensive Treatment
The purpose of this study is to determine the recommended Phase 2 dose and evaluate safety profile of cusatuzumab in combination with azacitidine in Japanese participants with treatment naïve acute myeloid leukemia (AML) who are…
- Trial name
- NCT04241549
- Testing
- Cusatuzumab, Azacitidine
- Where
- 5 sites in Japan
- Volunteers
- 6 people
- Sponsor
- OncoVerity, Inc.
Myelodysplastic Syndromes (MDS), Acute Myeloid Leukaemia (AML)
A Phase I/II Study of Gene-modified WT1 TCR Therapy in MDS & AML Patients
This is a Phase I/II trial to determine safety, clinical efficacy and feasibility of a gene-modified WT1 TCR therapy in patients with myelodysplastic syndrome (MDS) and acute myeloid leukaemia (AML).
- Trial name
- NCT02550535
- Testing
- Autologous WT1 TCR transduced T cells
- Where
- 6 sites in Belgium, Germany and 1 more
- Volunteers
- 3 people
- Sponsor
- Cell Medica Ltd
Acute Myeloid Leukemia (AML)
A Study of Venetoclax and Alvocidib in Patients With Relapsed/Refractory Acute Myeloid Leukemia
An open-label, dose-escalation study to assess the safety and pharmacokinetics (PK), to determine the dose limiting toxicity (DLT) and the recommended Phase 2 dose (RPTD), and to assess the preliminary efficacy of alvocidib with…
- Trial name
- NCT03441555
- Testing
- Venetoclax, Alvocidib
- Where
- 14 sites in United States, Germany and 1 more
- Volunteers
- 36 people
- Sponsor
- AbbVie
Leukemia, Myeloid, Acute
DFP-10917 in Combination With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia
This Phase I/II trial evaluates the safety and preliminary efficacy of DFP-10917 combined with venetoclax in relapsed or refractory acute myeloid leukemia.
- Trial name
- NCT06382168
- Testing
- DFP-10917, Venetoclax
- Where
- 4 sites in United States
- Volunteers
- 39 people
- Sponsor
- Delta-Fly Pharma, Inc.